- Tegobuvir
-
- $81.00 / 1mg
-
2025-05-22
- CAS:1000787-75-6
- Min. Order:
- Purity: 99.86%
- Supply Ability: 10g
|
| | 5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine Basic information |
| | 5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine Chemical Properties |
| Boiling point | 558.0±60.0 °C(Predicted) | | density | 1.46 | | storage temp. | Store at -20°C | | solubility | ≥24.95 mg/mL in DMSO; insoluble in H2O; ≥100 mg/mL in EtOH | | form | solid | | pka | 8.28±0.20(Predicted) | | color | White to off-white |
| | 5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine Usage And Synthesis |
| Uses | Tegobuvir is a specific, covalent inhibitor of the HCV NS5B polymerase. | | Biological Activity | Tegobuvir (GS-9190; TGV) is an orally active, non-cytotoxic imidazopyridine that, upon CYP-mediated intracellular activation, forms a glutathione conjugate th at acts as a covalent, potent and genotype 1 replicons-selective non-nucleoside inhibitor (NNI) against hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (IC50 = 0.8 nM/1b, 13.8 nM/1a, 21.9 μM/2a, >50 μM/1a; IC50 >100 nM against 2b, 3a, 4a, 5a, and 6a). When combined with suboptimal concentrations of other direct acting antivirals (DAAs) in cultures, tegobuvir (6-30 nM) is highly effective in curing cells from HCV replicon and in delaying or preventing the development of resistance against other DAAs. | | references | [1]. zeuzem s, andreone p, pol s, lawitz e, diago m, roberts s, focaccia r, younossi z, foster gr, horban a et al: telaprevir for retreatment of hcv infection. n engl j med 2011, 364(25):2417-2428.
[2]. wong ka, xu s, martin r, miller md, mo h: tegobuvir (gs-9190) potency against hcv chimeric replicons derived from consensus ns5b sequences from genotypes 2b, 3a, 4a, 5a, and 6a. virology 2012, 429(1):57-62.
[3]. shih ih, vliegen i, peng b, yang h, hebner c, paeshuyse j, purstinger g, fenaux m, tian y, mabery e et al: mechanistic characterization of gs-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis c virus ns5b polymerase. antimicrob agents chemother 2011, 55(9):4196-4203.
[4]. behrens se, tomei l, de francesco r: identification and properties of the rna-dependent rna polymerase of hepatitis c virus. embo j 1996, 15(1):12-22.
[5]. hebner cm, han b, brendza km, nash m, sulfab m, tian y, hung m, fung w, vivian rw, trenkle j et al: the hcv non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit ns5b polymerase function. plos one 2012, 7(6):e39163. |
| | 5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine Preparation Products And Raw materials |
|